Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Recurrence 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Myelodysplastic Syndromes 1Multiple Myeloma 1Leukemia, Myeloid, Acute 1

Interventions

Cyclophosphamide 88fludarabine phosphate 79Mycophenolic Acid 64Peripheral Blood Stem Cell Transplantation 62Whole-Body Irradiation 51Cyclosporine 50Tacrolimus 49Busulfan 45Antilymphocyte Serum 39Filgrastim 31Radiotherapy 27Methotrexate 27fludarabine 26Melphalan 26Cord Blood Stem Cell Transplantation 19Methylprednisolone 18Etoposide 16Sirolimus 14Granulocyte Colony-Stimulating Factor 14sargramostim 11Cyclosporins 11Therapeutics 10Stem Cell Transplantation 10Rituximab 10Flow Cytometry 10thymoglobulin 9Alemtuzumab 9Psychiatric Rehabilitation 8Cytarabine 8Transplantation 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Precursor Cell Lymphoblastic Leukemia-Lymphoma × gilteritinib × Plasma cell × Clear all
NCT04988555 2026-03-24

A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)

Sumitomo Pharma America, Inc.

Phase 1/2 Recruiting
606 enrolled
LymphoidMyeloidOther hematologic neoplasmPlasma cell

Multiple Myeloma, Myelodysplastic Syndromes, Recurrence, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡